New ads.

Showing posts with label Using. Show all posts
Showing posts with label Using. Show all posts

Wednesday, January 15, 2020

Living robots built using frog cells

African clawed frog, Xenopus laevis (stock image). | Credit: (c) Ezume Images / stock.adobe.com
African clawed frog, Xenopus laevis (stock image).

A book is made of wood. But it is not a tree. The dead cells have been repurposed to serve another need.
Now a team of scientists has repurposed living cells -- scraped from frog embryos -- and assembled them into entirely new life-forms. These millimeter-wide "xenobots" can move toward a target, perhaps pick up a payload (like a medicine that needs to be carried to a specific place inside a patient) -- and heal themselves after being cut.
"These are novel living machines," says Joshua Bongard, a computer scientist and robotics expert at the University of Vermont who co-led the new research. "They're neither a traditional robot nor a known species of animal. It's a new class of artifact: a living, programmable organism."
The new creatures were designed on a supercomputer at UVM -- and then assembled and tested by biologists at Tufts University. "We can imagine many useful applications of these living robots that other machines can't do," says co-leader Michael Levin who directs the Center for Regenerative and Developmental Biology at Tufts, "like searching out nasty compounds or radioactive contamination, gathering microplastic in the oceans, traveling in arteries to scrape out plaque."
The results of the new research were published January 13 in the Proceedings of the National Academy of Sciences.
Bespoke Living Systems
People have been manipulating organisms for human benefit since at least the dawn of agriculture, genetic editing is becoming widespread, and a few artificial organisms have been manually assembled in the past few years -- copying the body forms of known animals.
But this research, for the first time ever, "designs completely biological machines from the ground up," the team writes in their new study.
With months of processing time on the Deep Green supercomputer cluster at UVM's Vermont Advanced Computing Core, the team -- including lead author and doctoral student Sam Kriegman -- used an evolutionary algorithm to create thousands of candidate designs for the new life-forms. Attempting to achieve a task assigned by the scientists -- like locomotion in one direction -- the computer would, over and over, reassemble a few hundred simulated cells into myriad forms and body shapes. As the programs ran -- driven by basic rules about the biophysics of what single frog skin and cardiac cells can do -- the more successful simulated organisms were kept and refined, while failed designs were tossed out. After a hundred independent runs of the algorithm, the most promising designs were selected for testing.
Then the team at Tufts, led by Levin and with key work by microsurgeon Douglas Blackiston -- transferred the in silico designs into life. First they gathered stem cells, harvested from the embryos of African frogs, the species Xenopus laevis. (Hence the name "xenobots.") These were separated into single cells and left to incubate. Then, using tiny forceps and an even tinier electrode, the cells were cut and joined under a microscope into a close approximation of the designs specified by the computer.
Assembled into body forms never seen in nature, the cells began to work together. The skin cells formed a more passive architecture, while the once-random contractions of heart muscle cells were put to work creating ordered forward motion as guided by the computer's design, and aided by spontaneous self-organizing patterns -- allowing the robots to move on their own.
These reconfigurable organisms were shown to be able move in a coherent fashion -- and explore their watery environment for days or weeks, powered by embryonic energy stores. Turned over, however, they failed, like beetles flipped on their backs.
Later tests showed that groups of xenobots would move around in circles, pushing pellets into a central location -- spontaneously and collectively. Others were built with a hole through the center to reduce drag. In simulated versions of these, the scientists were able to repurpose this hole as a pouch to successfully carry an object. "It's a step toward using computer-designed organisms for intelligent drug delivery," says Bongard, a professor in UVM's Department of Computer Science and Complex Systems Center.
Living Technologies
Many technologies are made of steel, concrete or plastic. That can make them strong or flexible. But they also can create ecological and human health problems, like the growing scourge of plastic pollution in the oceans and the toxicity of many synthetic materials and electronics. "The downside of living tissue is that it's weak and it degrades," say Bongard. "That's why we use steel. But organisms have 4.5 billion years of practice at regenerating themselves and going on for decades." And when they stop working -- death -- they usually fall apart harmlessly. "These xenobots are fully biodegradable," say Bongard, "when they're done with their job after seven days, they're just dead skin cells."
Your laptop is a powerful technology. But try cutting it in half. Doesn't work so well. In the new experiments, the scientists cut the xenobots and watched what happened. "We sliced the robot almost in half and it stitches itself back up and keeps going," says Bongard. "And this is something you can't do with typical machines."
Cracking the Code
Both Levin and Bongard say the potential of what they've been learning about how cells communicate and connect extends deep into both computational science and our understanding of life. "The big question in biology is to understand the algorithms that determine form and function," says Levin. "The genome encodes proteins, but transformative applications await our discovery of how that hardware enables cells to cooperate toward making functional anatomies under very different conditions."
To make an organism develop and function, there is a lot of information sharing and cooperation -- organic computation -- going on in and between cells all the time, not just within neurons. These emergent and geometric properties are shaped by bioelectric, biochemical, and biomechanical processes, "that run on DNA-specified hardware," Levin says, "and these processes are reconfigurable, enabling novel living forms."
The scientists see the work presented in their new PNAS study -- "A scalable pipeline for designing reconfigurable organisms," -- as one step in applying insights about this bioelectric code to both biology and computer science. "What actually determines the anatomy towards which cells cooperate?" Levin asks. "You look at the cells we've been building our xenobots with, and, genomically, they're frogs. It's 100% frog DNA -- but these are not frogs. Then you ask, well, what else are these cells capable of building?"
"As we've shown, these frog cells can be coaxed to make interesting living forms that are completely different from what their default anatomy would be," says Levin. He and the other scientists in the UVM and Tufts team -- with support from DARPA's Lifelong Learning Machines program and the National Science Foundation -- believe that building the xenobots is a small step toward cracking what he calls the "morphogenetic code," providing a deeper view of the overall way organisms are organized -- and how they compute and store information based on their histories and environment.
Future Shocks
Many people worry about the implications of rapid technological change and complex biological manipulations. "That fear is not unreasonable," Levin says. "When we start to mess around with complex systems that we don't understand, we're going to get unintended consequences." A lot of complex systems, like an ant colony, begin with a simple unit -- an ant -- from which it would be impossible to predict the shape of their colony or how they can build bridges over water with their interlinked bodies.
"If humanity is going to survive into the future, we need to better understand how complex properties, somehow, emerge from simple rules," says Levin. Much of science is focused on "controlling the low-level rules. We also need to understand the high-level rules," he says. "If you wanted an anthill with two chimneys instead of one, how do you modify the ants? We'd have no idea."
"I think it's an absolute necessity for society going forward to get a better handle on systems where the outcome is very complex," Levin says. "A first step towards doing that is to explore: how do living systems decide what an overall behavior should be and how do we manipulate the pieces to get the behaviors we want?"
In other words, "this study is a direct contribution to getting a handle on what people are afraid of, which is unintended consequences," Levin says -- whether in the rapid arrival of self-driving cars, changing gene drives to wipe out whole lineages of viruses, or the many other complex and autonomous systems that will increasingly shape the human experience.
"There's all of this innate creativity in life," says UVM's Josh Bongard. "We want to understand that more deeply -- and how we can direct and push it toward new forms."

Story Source:
Materials provided by University of Vermont. Original written by Joshua E. Brown. Note: Content may be edited for style and length.

Saturday, November 30, 2019

Using fungi to search for medical drugs

Wild mushrooms

An enormous library of products derived from more than ten thousand fungi could help us find new drugs. Researchers from the group of Jeroen den Hertog at the Hubrecht Institute, in collaboration with researchers from the Westerdijk Institute and Utrecht University, have set up this library and screened it for biologically active compounds. They tested the biological activity of these fungal products first using zebrafish embryos. The researchers chose to use zebrafish embryos, because it allows the analysis of effects on many cell types at the same time, in a working body, and because zebrafish are physiologically very similar to humans. They have already found various known compounds, among which the cholesterol lowering drug lovastatin. The library of fungal products offers ample opportunity to search for new drugs.
The results of this research were published on the 26th of November in the scientific journal Scientific Reports.
Fungal products
We constantly need new therapeutic compounds in the clinic for various reasons, including our increasing age, with corresponding illnesses, and resistance to existing drugs. Fungi are an excellent, but underexplored source of these kinds of compounds, such as lovastatin, a compound produced by the fungus Aspergillus terreus and that is used as a cholesterol lowering drug. Jelmer Hoeksma, one of the researchers at the Hubrecht Institute, explains: "Every year new compounds produced by fungi are identified, but so far we have only investigated a very small subset of all existing fungi. This suggests that many more biologically active compounds remain to be discovered."
Ten thousand fungi
The collaboration with the Westerdijk Fungal Biodiversity Institute, home to the largest collection of live fungi in the world, enabled the researchers to set up a large library of filtrates derived from more than ten thousand different fungi. A filtrate contains all the products that the fungus excretes. To search for therapeutic compounds, the researchers investigated the effects of this large library of fungal products first on zebrafish embryos. The zebrafish embryos enabled the researchers to study effects on the whole body during development. Zebrafish are vertebrates that are physiologically very similar to humans and are often used to test drugs for a variety of disorders. Within a few days these embryos develop most of their organs, making biological activity of the fungal compounds readily detectable. In addition, comparison to known drugs may result in identification of new drugs and also point towards the underlying mechanisms of action of these compounds.
Pigmentation
The researchers found 1526 filtrates that contain biologically active compounds with an effect on zebrafish embryos, from which they selected 150 filtrates for further analysis. From these, they isolated 34 known compounds, including the cholesterol lowering drug lovastatin, which was produced by the fungus Resinicium furfuraceum. Until now it was unknown that this fungus produces lovastatin. In addition, the researchers found filtrates that affect pigmentation in zebrafish embryos. Other studies have shown that factors involved in pigmentation can also play a crucial role in the development of skin cancer. The researchers are currently isolating the active compounds that cause pigmentation defects in zebrafish embryos from the filtrates.
Tip of the iceberg
This study underlines the large variety of biologically active compounds that are produced by fungi and the importance of further investigating these compounds in the search for new drugs. Hoeksma: "The large library of fungal filtrates that we have set up can also be tested in many other systems, such as models for antibiotic resistance in bacteria and tumor development, making this study only the tip of the iceberg."

Story Source:
Materials provided by Hubrecht InstituteNote: Content may be edited for style and length.

Thursday, November 28, 2019

Teens are using a highly potent form of marijuana

Cannabis sativa plant

Nearly one in four Arizona teens have used a highly potent form of marijuana known as marijuana concentrate, according to a new study by Arizona State University researchers.
Among nearly 50,000 eighth, 10th, and 12th graders from the 2018 Arizona Youth Survey, a biennial survey of Arizona secondary school students, one-third (33%) had tried some form of marijuana, and nearly a quarter (24%) had tried marijuana concentrate.
Marijuana concentrates have about three times more THC, the constituent of marijuana that causes the "high," than a traditional marijuana flower. This is concerning because higher doses of THC have been linked to increased risk of marijuana addiction, cognitive impairment and psychosis, said the study's lead researcher, Madeline Meier, an ASU assistant professor of psychology.
The research team also found that teens who used concentrates had more risk factors for addiction. The researchers compared teens who had used marijuana concentrates with teens who had used some form of marijuana but not marijuana concentrates and teens who had never used any form of marijuana on known risk factors for addiction, such as lower perceived risk of harm of marijuana, peer substance use, parental substance use, academic failure and greater perceived availability of drugs in the community. They found that teens who had used marijuana concentrates were worse off on every addiction risk factor.
"This is important because it shows that teens who have a diverse array of risk factors for developing marijuana addiction may be further amplifying their risk for addiction by using high-THC marijuana concentrates," explained study co-author, Dustin Pardini, an associate professor in ASU's School of Criminology & Criminal Justice.
The study "Cannabis Concentrate Use in Adolescents," is published in the early online edition (Aug. 26, 2019) of Pediatrics.
The team -- which includes ASU researchers Meagan Docherty, School of Criminology & Criminal Justice; Scott Leischow, College of Health Solutions; and Kevin Grimm, Department of Psychology -- also found that teens who had used concentrates had much higher rates of e-cigarette use. One explanation for this might be that teens are using e-cigarettes to vape marijuana concentrate, according to Meier. Earlier studies, including those by Meier, have shown that youth put marijuana in e-cigarettes to conceal their marijuana use.
"Vaping marijuana can be passed off as nicotine vaping," Meier explained.
This finding reinforces the recent decision by the Food and Drug Administration to impose new restrictions on e-cigarettes and their constituents as a means of reducing marijuana use, according to the researchers.
Marijuana concentrates don't look like the traditional marijuana flower. Concentrates can look like wax, oil, or a brittle substance that shatters easily.
"What concerns me most is that parents might have no idea that their child is using marijuana, especially if their child is using marijuana concentrate," said Meier. "Marijuana is not harmless, particularly for adolescents."
Meier's earlier research suggests that frequent marijuana use from adolescence through adulthood is associated with IQ decline. Pardini's prior research has linked regular marijuana use during adolescence with the emergence of persistent subclinical psychotic symptoms.
The researchers' next steps are to ascertain if concentrate users do in fact exhibit higher rates of addiction, cognitive impairment and psychosis.
The Arizona Youth Survey is administered by the Arizona Criminal Justice Commission (ACJC) through funds appropriated by the Arizona Legislature.

Tuesday, November 26, 2019

Using fungi to search for medical drugs

Using fungi to search for medical drugs

An enormous library of products derived from more than ten thousand fungi could help us find new drugs. Researchers from the group of Jeroen den Hertog at the Hubrecht Institute, in collaboration with researchers from the Westerdijk Institute and Utrecht University, have set up this library and screened it for biologically active compounds. They tested the biological activity of these fungal products first using zebrafish embryos. The researchers chose to use zebrafish embryos, because it allows the analysis of effects on many cell types at the same time, in a working body, and because zebrafish are physiologically very similar to humans. They have already found various known compounds, among which the cholesterol lowering drug lovastatin. The library of fungal products offers ample opportunity to search for new drugs. The results of this research were published on the 26th of November in the scientific journal Scientific Reports.
Fungal products
We constantly need new therapeutic compounds in the clinic for various reasons, including our increasing age, with corresponding illnesses, and resistance to existing drugs. Fungi are an excellent, but underexplored source of these kinds of compounds, such as lovastatin, a compound produced by the fungus Aspergillus terreus and that is used as a cholesterol lowering drug. Jelmer Hoeksma, one of the researchers at the Hubrecht Institute, explains: "Every year new compounds produced by fungi are identified, but so far we have only investigated a very small subset of all existing fungi. This suggests that many more biologically active compounds remain to be discovered."
Ten thousand fungi
The collaboration with the Westerdijk Fungal Biodiversity Institute, home to the largest collection of live fungi in the world, enabled the researchers to set up a large library of filtrates derived from more than ten thousand different fungi. A filtrate contains all the products that the fungus excretes. To search for therapeutic compounds, the researchers investigated the effects of this large library of fungal products first on zebrafish embryos. The zebrafish embryos enabled the researchers to study effects on the whole body during development. Zebrafish are vertebrates that are physiologically very similar to humans and are often used to test drugs for a variety of disorders. Within a few days these embryos develop most of their organs, making biological activity of the fungal compounds readily detectable. In addition, comparison to known drugs may result in identification of new drugs and also point towards the underlying mechanisms of action of these compounds.
Pigmentation
The researchers found 1526 filtrates that contain biologically active compounds with an effect on zebrafish embryos, from which they selected 150 filtrates for further analysis. From these, they isolated 34 known compounds, including the cholesterol lowering drug lovastatin, which was produced by the fungus Resinicium furfuraceum. Until now it was unknown that this fungus produces lovastatin. In addition, the researchers found filtrates that affect pigmentation in zebrafish embryos. Other studies have shown that factors involved in pigmentation can also play a crucial role in the development of skin cancer. The researchers are currently isolating the active compounds that cause pigmentation defects in zebrafish embryos from the filtrates.
Tip of the iceberg
This study underlines the large variety of biologically active compounds that are produced by fungi and the importance of further investigating these compounds in the search for new drugs. Hoeksma: "The large library of fungal filtrates that we have set up can also be tested in many other systems, such as models for antibiotic resistance in bacteria and tumor development, making this study only the tip of the iceberg."

Story Source:
Materials provided by Hubrecht InstituteNote: Content may be edited for style and length.